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SUMMARY
The inclusion of medical costs in life years gained in economic evaluations of health care technologies has long been
controversial. Arguments in favour of the inclusion of such costs are gaining support, which shifts the question
from whether to how to include these costs. This paper elaborates on the issue how to include cost in life years
gained in cost effectiveness analysis given the current practice of economic evaluations in which costs of related
diseases are included. We combine insights from the theoretical literature on the inclusion of unrelated medical costs
in life years gained with insights from the so-called ‘red herring’ literature. It is argued that for most interventions it
would be incorrect to simply add all medical costs in life years gained to an ICER, even when these are corrected for
postponement of the expensive last year of life. This is the case since some of the postponement mechanism is
already captured in the unadjusted ICER by modelling the costs of related diseases. Using the example of smoking
cessation, we illustrate the differences and similarities between different approaches. The paper concludes with a
discussion about the proper way to account for medical costs in life years gained in economic evaluations.
Copyright r 2010 John Wiley & Sons, Ltd.
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1. INTRODUCTION
When a successful intervention adds a few years to the life of some patient, this patient is bound to
consume medical care during these years. Some of these costs may be directly related to the
intervention. For instance, if the person had a life saving open heart surgery and would subsequently
have to be treated for an infection of the wound on his chest, such costs are directly related to the
surgery. Other costs, however, are unrelated to the intervention under study. For instance, if the same
person while biking would fall due to a dog suddenly crossing the road and breaks a hip, the costs of
treatment of the hip fracture are unrelated to the intervention. But still, without the successful
heart surgery, obviously, the person would never have incurred these costs. The inclusion of these latter
*Correspondence to: Department of Health Policy & Management and Institute for Medical Technology Assessment, Erasmus
University, Rotterdam, The Netherlands. E-mail: pieter.van.baal@rivm.nl
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costs, the unrelated medical costs in life years gained, also called indirect medical costs, has long been
controversial (Russell, 1986; Garber and Phelps, 1997; Meltzer, 1997; Weinstein and Manning, 1997;
Nyman, 2004; van Baal et al., 2007b; Meltzer, 2008; Lee, 2008; Feenstra et al., 2008; Rappange
et al., 2008).
A ﬁrst area of controversy relates to the deﬁnition of unrelated costs, which differs between the
theoretical and the more practical literature on economic evaluations. In the theoretical debate, future
unrelated medical costs are labelled as conditionally independent, implying that their height is not
inﬂuenced by the intervention under study and depend, conditional on survival, exclusively on age
(Garber and Phelps, 1997). It has been shown that inclusion of these conditionally independent costs is
consistent with welfare maximization (Meltzer, 1997, 2008) and as long as the projections of length of
added life and quality of life during added years (implicitly) assume normal care consumption, it would
be inconsistent not to include the costs of such care (Nyman, 2004). Furthermore, including future
medical costs as well as the health effects of that future medical spending results in ratios that are
optimally informative for decision makers (van Baal et al., 2007b). Only if an increase in the duration of
life is accompanied by an increase in income, which covers all medical and non-medical expenses in
added time, theoretically, a case could be made to exclude future unrelated medical costs, but this seems
unrealistic to assume as a rule (Lee, 2008; Feenstra et al., 2008; Rappange et al., 2008). Concluding,
there is growing consensus in the theoretical literature that future unrelated medical costs need to be
included in cost effectiveness analyses. The obvious question then arises: how should we include them in
practice? To answer this we have to understand how ageing of the population affects health care costs
and what medical costs are usually included in economic evaluations.
In that context a second stream of literature, namely that on increases in health care costs due to
ageing, is important. In recent years a lot of research has been performed studying the impact of ageing
on health care expenditure from a macro perspective. In this area, an inﬂuential paper was published by
(Zweifel et al., 1999). They analysed the relationship between age and health care expenditure and found
that health care expenditure depends importantly on proximity to death rather than age. Since higher
average health care costs at older age are caused mainly by the fact that relatively many elderly people
die, with associated intensive healthcare use and costs in the last period of life, they dubbed this the ‘red
herring’ hypothesis (Seshamani and Gray, 2004a,b Hakkinen et al., 2008; Spillman and Lubitz, 2000;
Polder et al., 2006). Obviously, these results have direct relevance for the question of how to include
unrelated medical costs in added life years in economic evaluations. This was recognised by Gandjour
and Lauterbach, who used these results to show that cost-effectiveness analyses potentially overestimate
the incremental cost-effectiveness ratio (ICER) of preventive interventions when including unrelated
medical costs in economic evaluations, if, in doing so, the high costs of the last year of life, which are
postponed by prevention, are not explicitly modelled (Gandjour and Lauterbach, 2005). Using
Medicare data they estimated that the cost-effectiveness ratio of preventive interventions may decrease
up to US $11 000. They do, however, make one important simplifying assumption in their analyses, i.e.
that in economic evaluations (of preventive interventions) it is common practice to include both related
and unrelated costs in life years gained and to model those costs exclusively depending on age.
However, here, the third relevant stream of literature comes into play, i.e. that regarding practical
economic evaluations. Typically, as prescribed in many (pharmaco-economic) guidelines (e.g. CVZ,
2005; Gold et al., 1996; NICE, 2008), cost-effectiveness analyses will only include related costs in life
years gained while deliberately ignoring changes in unrelated costs altogether (e.g. Godfrey et al., 2005;
Mihaylova et al., 2006). However, the costs that are termed ‘related’ and therefore included in practice
do not necessarily adhere to the theoretical deﬁnitions of ‘related’. In practice in economic evaluations
related costs are usually deﬁned on the level of diseases. Only the costs of diseases at which the
intervention is targeted are taken into account. For instance, in an economic evaluation of statins for
the treatment of cardiovascular disease, usually all costs of cardiovascular disease are labelled as related
and included in the economic evaluation. For prevention aiming at risk factors, usually, costs of
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diseases to which the risk factor is causally related are included. Thus, for a weight loss intervention,
typically costs of diabetes and cardiovascular disease are included. The fact that costs of related diseases
are not equivalent to related costs highlights a difference between the theoretical literature in this area
and the practice of economic evaluations.
Given that costs of related diseases normally are already included in practical economic evaluations,
it is incorrect to add all medical costs in life years gained to the ICER, even when corrected for the costs
in the last year of life as suggested by Gandjour and Lauterbach, for two reasons: (i) the only costs that
need to be added to the ICER in this context are the costs of unrelated diseases, since the costs of related
diseases are already included and adding them again results in double-counting. Moreover, (ii) if the
related costs are due to lethal diseases (i.e. diseases that inﬂuence survival), as they must when the
intervention prolongs life, some of the postponement mechanism is already captured in the ICER. To
illustrate the problem consider the following extreme example. Suppose that there exist only two
diseases: one is lethal (e.g. cancer) and the other causes only a reduction in quality of life (e.g.
osteoarthritis). Now suppose an intervention postpones the onset of cancer for ﬁve years, increasing life-
expectancy from age 80 to 85 for people with osteoarthritis, and assume that the treatment costs of
osteoarthritis increase with age. The intervention causes savings in the costs of cancer in normal years
(the years lived up to the year of death at age 80) and additional costs in added years (years lived from
81 to age 85) for both cancer and osteoarthritis. Thus, the higher costs of the last year of life are
postponed by the intervention. A standard economic evaluation would account for the related lifetime
costs of cancer (which are postponed), but ignore the costs of osteoarthritis in life years gained. Then,
obviously, adding the annual age-speciﬁc health care costs for the ages 80–85 would lead to double
counting of costs of cancer. Moreover, applying the correction as proposed by Gandjour and
Lauterbach in common economic evaluations, which include costs of related diseases, would also lead
to incorrect adjustment of the ICER. Both the savings in normal life years and the costs in life years
gained due to postponement of cancer are already taken into account. The only adjustment needed is
the inclusion of osteoarthritis costs in life years gained and it sufﬁces to model these conditional on age
only. Since the costs of osteoarthritis obviously depend solely on age, they do not need to be corrected
for postponement of costs in the last year of life.
In terms of the theoretical (although perhaps not very practically useful) deﬁnition of unrelated costs
(as ﬁrst put forward by Garber and Phelps, 1997), i.e. conditional independence of costs, in the above
example the costs of cancer are related (i.e. conditionally dependent) because they do not depend on age
but on time to death. Furthermore, the fact that the costs of osteoarthritis increase with age does not
imply that they are dependent. The costs of osteoarthritis conditional on reaching a particular age are,
in fact, independent of the intervention targeted at cancer. Therefore, they are conditionally
independent. More generally, if an intervention extends life, all costs that fully depend on time to
death are postponed and, theoretically, can be labelled related. Consequently, the costs that depend
exclusively on age can be called unrelated. In the above example, conveniently, the distinction between
related and unrelated costs matches with the distinction between related and unrelated diseases. In
reality, however, costs of speciﬁc diseases do not depend exclusively on age or time to death, which
complicates the separation of related and unrelated costs considerably. For example, costs of cancer in
life years gained could include costs of a screening program on cancer that everybody in the population
at that age would receive (implying conditional independence).
This paper elaborates on the issue how to include cost in life years gained in common practical cost
effectiveness analysis and discusses how ICERs can be adjusted for postponement of the costs in the last
year of life if costs of related diseases are already taken into account in the basic economic evaluation. It
therefore combines the theoretical literature in this area with the practice of economic evaluations. The
structure of the paper is as follows. First, the following section sets out a theoretical framework in which
we confront the theoretical debate on unrelated medical care with the so-called ‘red herring’ claim and
the practice of economic evaluations in which costs of related diseases are included. Then, using the
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example of smoking cessation, we demonstrate the similarities between the ‘red herring’ approach and
the disease-speciﬁc approach. The paper concludes with a discussion about the proper way to account
for medical costs in life years gained in economic evaluations. In our paper, a health care perspective is
taken. However, for a societal perspective, the reasoning is completely analogous.
2. THEORETICAL FRAMEWORK
In this section, we will try to reconcile the practice of economic evaluation with the empirical ﬁndings on
the health care costs of ageing under the now more broadly accepted assumption (Rappange et al.,
2008) that both related and unrelated medical costs should be included. To do this, we will use the
example of an individual, whose death is postponed if he receives intervention y instead of intervention
x at age q. After intervention x this individual will die at age v and after intervention y this person dies at
age w. The intervention y results in ‘added’ years that equal w minus v (see Figure 1).
Taking a health care perspective, excluding all costs but those falling under the health care budget, an
ICER of intervention y compared with intervention x consistent with maximization of health gains from




Here, for simplicity, it is assumed that costs of the intervention oc (e.g. costs of vaccines, nicotine gum
or surgery with oc(y) and oc(x) denoting the intervention costs of intervention y and x respectively) can
be separated from all other lifetime health care costs lhc (with lhc(x) and lhc(y) denoting the lifetime
health care costs for intervention x and y respectively). For the remainder of this paper, we will focus on
the estimation of incremental lifetime health care costs lhc and the implications thereof for the ICER.
The simplest way to estimate lifetime health care costs is to model total health care costs as a function
of age only. If health care costs depend solely on age, costs in ‘normal’ years (v-q) are identical for






























Figure 1. Life years under interventions x and y
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with ac(i) the average health care expenditure at age i. This is the approach as perceived by Gandjour
and Lauterbach to be current practice in the economic evaluation of preventive interventions. However,
if the costs differ whether one survives or dies at a particular age, and given that the costs in the last year














where dc(i) denotes costs in the last year of life i and sc(i) denotes health care costs during all other
years. By deﬁnition under intervention y there are no costs in the last year of life during ‘normal’ years
(the years lived under both interventions v-q), because this person dies at a later age (w). Furthermore,
the costs in normal years are lower under intervention y than intervention x since it does not contain the




i¼q scðiÞ. Thus, by explicitly modeling the last
year of life an intervention ﬁrst results in savings during ‘normal years’. However, after normal years,
one incurs extra costs in ‘added years’:
Pw1
i¼v11 scðiÞ1dcðwÞ. The difference between modelling costs
exclusively depending on age and modelling costs also depending on the last year of life was the
situation addressed by Gandjour and Lauterbach. Since, in general, health care costs increase
exponentially at old age, on balance, modelling costs exclusively conditional on age results in an
overestimation of incremental health care costs. However, as we will argue, in most economic
evaluations, costs are modelled differently, and adjusting ICERs is not as straightforward as seems to be
suggested by Gandjour and Lauterbach.
Usually in economic evaluations it is not the costs that are disentangled into a related and an
unrelated component, but the diseases that are categorised as related or not. Related diseases are
deﬁned as the diseases at which the intervention investigated is targeted (Gold et al., 1996) and all other
diseases are deﬁned as unrelated to the intervention. As noted before, this deﬁnition of related and
unrelated does not necessarily adhere to the strict deﬁnition of conditional dependence and
independence. Using this framework, lhc is the sum of related diseases and unrelated diseases and we

































fucði; fjyÞ  ucði; fjxÞg
ð3Þ
where rc(i,e|x) denotes the costs at age i of related disease e under intervention x, and uc(i,f|x)
denotes the costs of unrelated disease f at age i under intervention x. If costs of unrelated diseases
are truly independent, unrelated medical costs should be equal in normal years for interventions
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frcði; ejyÞ  rcði; ejxÞg ð4Þ
If intervention y postponed or avoids disease, the costs of related diseases in normally lived life years

















f¼1 ucði; fjyÞ is positive and therefore, ignoring this term results in an
underestimate of the ICER, ceteris paribus.
Modelling health care costs as a function of age and time to death has been the primary tool in
projections of future health care costs while modelling costs conditional on disease status is used within
health economic evaluations. However, these different approaches can be put into a common
framework (see Figure 2).
In Figure 2 health care costs are assumed to be a consequence of disease. This implies that the
relation between proximity to death and health care costs is driven by the relation between the costs of
individual diseases and proximity to death. As can be seen from Figure 2, if an intervention postpones
death by postponement or avoidance of a disease or improved disease prognosis, this will result in
postponement of costs. This can be modelled either conditional on disease status or conditional on time
to death.
Comparing Equations (2) and (3) demonstrates that for a life-saving intervention, both the red
herring approach and the disease-speciﬁc approach results in savings in ‘normal’ years and extra costs in
‘added’ years.
Now let us turn to the question as to how to adjust an ICER that already includes the lifetime costs
of related diseases (as in Equation (4)). Straightforward addition of all costs stratiﬁed by survivors and
decedents to a standard ICER that includes costs of related diseases results in double counting of




e¼1 frcði; ejyÞ  rcði; ejxÞg and double counting of costs






e¼1 rcði; ejyÞ resulting in the following expression:



















Figure 2. Relation between intervention, mortality and health care costs
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Subsequently, the question is how to adjust Dlhc estimated as in Equation (4) for the costs of
unrelated diseases. Explicit modelling of all unrelated diseases is an unpractical approach. A more
practical approach is to use total health care expenditure as a starting point. Then, ﬁrst, costs of related
diseases can be subtracted from total health care costs. Second, it should be investigated whether the
relation between time to death and health care costs is altered after the costs of related diseases are
excluded. This will demonstrate the extent to which the related illnesses have captured the
postponement effect and, consequently, to what extent this postponement effect is already captured
in the estimations. If related diseases include some major causes of death, the relation between unrelated
diseases and time to death probably is weaker than the relation between total costs and time to death.
The question is whether the relation is still strong enough to warrant correction for the last year of life.
Note that this problem arises because of the fact that although, in theory, unrelated costs should depend
solely on age, this will not as a rule be the case for costs of unrelated diseases. Unrelated costs is a
different concept than that of the costs of unrelated diseases, implying that normally not all death-
related costs are included in the costs of related diseases.
In the next section we highlight the practical implications of these different approaches using the
example of smoking cessation.
3. CASE STUDY: SMOKING CESSATION
3.1 Methods
This section demonstrates the effects of using different methodologies to calculate lifetime health care
costs by the example of a smoking cessation intervention. We show that the disease-speciﬁc approach
and the red herring approach both capture the same postponement mechanism. The intervention
evaluated is increased implementation of a smoking cessation intervention, Minimal counselling by a
GP and/or a GP-assistant in combination with nicotine replacement therapy in Dutch adult smokers
(Silagy et al., 2002). Details of how we modelled this intervention were published previously (Feenstra
et al., 2005). In short, a current practice scenario (CP) was deﬁned as the mixture of all current
initiatives to stop smoking and willpower alone. In an intervention scenario, during 1 year, 25% of all
smokers between 60 and 64 were given minimal counselling with nicotine replacement therapy and
showed increased cessation rates. To estimate QALYs and health care costs for the current practice and
intervention scenario, the RIVM Chronic Disease Model (CDM) was used (see Appendix) (Hoogenveen
et al., in press; van Baal et al., 2006; Hoogenveen et al., 2008). ICERs were then calculated for different
values of the discount rate as advised by Dutch, British and American guidelines (CVZ, 2005; Claxton
et al., 2006; Gold et al., 1996).
Estimates of lifetime health care costs using the CDM were based on the data of the Costs of Illness
in the Netherlands study (Slobbe et al., 2006; van Baal et al., 2008, 2007b). By partitioning the costs of
illness data in different ways (see Appendix) we could estimate the following ﬁve ICERs (for ease of
notation we have omitted summation indices in the ICERS, e.g. rc(x) denotes the lifetime health costs
of all related disease under intervention x):
1. ICER 1 assumes that lifetime health care costs of all diseases are taken into account but that they




Gandjour and Lauterbach assumed this ICER to be used in most economic evaluations of
preventive care.
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2. ICER2 also takes total health care expenditure into account, but now models the expensive




This ratio was proposed by Gandjour and Lauterbach as an improvement of ICER1. This
ratio takes into account the postponement of health care costs.
3. ICER3 is most often seen in economic evaluation and includes costs of related diseases in
normal as well as added life years as in Equation (4). Costs of unrelated diseases are not




This ratio accounts for postponement of the costs of related diseases, but ignores costs of
unrelated diseases.
4. ICER4 completes ICER3 by adding the costs of unrelated diseases as in Equation (3). The




5. ICER5 constitutes a correction of ICER3 using costs of survivors and decedents but ignoring




ICER5 involves double counting of savings in normal years and extra costs in added years.
Based on our theoretical framework, we would expect that ICER1 is highest since it ignores savings
in normal years and that ICER3 is lowest since only the costs of related diseases are taken into account
in which we expect savings. We expected that the values for ICER2 and ICER4 would be in close range
since both capture the same postponement mechanism and would result ﬁrst in savings and then in extra
costs. We did not have an a priori hypothesis whether ICER5 would be lower or higher than ICER4.
3.2 Results
Figure 3 displays differences in health care costs over time due to the smoking cessation intervention.
Figure 3 illustrates that if lifetime health care costs are estimated as a function of age only,
prevention does not result in savings in the short run and thus ignores the postponement component of
prevention. The differences in the costs of survivors and the costs of unrelated disease follow a similar
pattern as they also depend on age exclusively. More importantly, it is observable that both the costs of
related diseases and the costs in the last year of life are postponed by the intervention. However, if costs
are calculated conditional on disease status, short run savings are higher while long run additional costs
are lower. A possible explanation for this phenomenon might be that modelling costs conditional on
disease status allows for differential effects of interventions on health care costs, for instance, that
expensive causes of death are replaced by cheaper causes of death. In case of smoking, expensive causes
of death such as lung cancer and COPD are replaced by cheaper causes of death such as coronary heart
POSTPONEMENT OF HEALTH CARE COSTS 439
Copyright r 2010 John Wiley & Sons, Ltd. Health Econ. 20: 432–445 (2011)
DOI: 10.1002/hec
disease. These more reﬁned mechanisms cannot always be picked up by the proximity to death
approach.
Table I gives the different ICERs of the smoking cessation intervention example for discount rates as
used in the Netherlands, USA and the UK.
Table I shows that ICER1 is highest and ICER3 is lowest for all values of the discount rate.
Moreover, ICER2 and ICER4 produce similar results. ICER5 is lower than ICER2 and ICER4
showing that, on balance, the double counting of savings in normal life years and costs in added years
results on balance only in a slight underestimation of the ICER for this speciﬁc example.
4. DISCUSSION AND CONCLUSIONS
In this paper, we have discussed the difﬁculties and different approaches related to the inclusion of costs in
life years gained in economic evaluations, combining insights from the theoretical debates and the ‘red
herring’ literature, as well as considering the practice of current economic evaluations. Importantly, cost-
effectiveness analyses overstate the cost-effectiveness ratio of life-saving interventions if they do not explicitly














2020 2030 2040 2050
Figure 3. Difference in health care costs over time (excluding costs of the smoking cessation intervention) due to
smoking cessation intervention (discount rate 4%)
Table I. Incremental cost effectiveness ratios (ICER) expressed in h per QALY gained of smoking cessation
intervention for different discount rates
Dutch guidelines US guidelines UK guidelines
Discount rate costs 4% 3% 3.5%
Discount rate effects 1.5% 3% 3.5%
ICER1 (simple approach: age-related costs only) 14 200 22 000 22 200
ICER2 (simple approach accounting for time to death) 11 900 18 500 18 600
ICER3 (standard approach: costs of related diseases) 2600 3200 3600
ICER4 (standard approach accounting for unrelated diseases) 10 400 16 100 16 200
ICER5 (double counting) 9600 15 100 15 100
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evaluations already a part of this postponement mechanism is taken into account if studies include lifetime
cost differences of so-called related diseases. If an intervention extends life, some costs of related diseases
usually are avoided altogether, while others are postponed. This mechanism is already captured by explicit
modelling of these diseases and their costs. Adding costs of survivors and descendents using a red herring
approach may result in double counting of both the savings in normal live years and the costs in life years
gained. Since both savings as well as costs may be double-counted, these both effects may, to some –
unknown and probably intervention speciﬁc – extent, cancel out. In our example this resulted, on balance,
only in a slight underestimation of the ICER. However, it is important to be aware of these two different
approaches, since mixing them may result in conceptually wrong cost-effectiveness ratios and over-
correction. Since the differences and therefore the misrepresentation of true cost-effectiveness may be more
pronounced in other cases, this issue ultimately is also important in the context of health policy and decision
making. Indeed, ignoring or misrepresenting the here discussed costs and savings may result in non-optimal
decisions when they push an ICER unduly above or below the relevant threshold in a speciﬁc jurisdiction.
Hence, clarity about how these costs were included in an analysis is warranted.
If we apply the theoretical deﬁnition of conditional independence, unrelated medical costs in life years
gained should be independent of time to death. However, in economic evaluations typically not the costs
are disentangled into a related and an unrelated component, but rather the diseases. The two are,
however, clearly not the same, implying that many practical applications of economic evaluations include
wrong estimates of ‘related costs’. Thus, in practice not all costs that are related are taken into account in
economic evaluations since only costs of the diseases at which the intervention is targeted are included.
The question then becomes how to account for the costs of unrelated diseases in life years gained. Are
their costs dependent on proximity to death too? We hypothesise that the relation between time to death
and health care costs may differ per disease. Furthermore, we hypothesise that the relation between time
to death and health care costs is strongest for diseases that increase mortality rates. This implies that if
related diseases include some major causes of death (like in our smoking example), the relation between
unrelated diseases and time to death is (much) weaker than the relation between total costs and time to
death and an additional correction for the last year of life might be superﬂuous. Using the example of
smoking cessation we showed that if unrelated diseases were modelled conditional on age only, a
proximity to death methodology produced similar results as a disease-speciﬁc approach. However, for
other analyses that included a more limited set of related diseases, it might still be important to correct
for time to death to estimate the costs of unrelated diseases. In theory, an attractive option for updating
economic evaluations would be to combine the two approaches, which requires assessing the effect of age
and time to death on health expenditures for each disease separately. This crucially depends on the
availability of rather detailed longitudinal data, including disease status measured repeatedly. In the
absence of these disease-speciﬁc ‘red herrings’, calculated in a systematic way, a more opportunistic and
feasible approach seems to be to deliberately choose one of the two methods set out above.
We argue that the separation of costs into a related and unrelated component is unnecessary and
creates more problems than it solves. This is especially the case given the current state of affairs in
economic evaluations to include the costs of related diseases instead of related costs. If one wishes to
update these common ICERS, the discussed problems may occur. If all lifetime health care costs are
included in an economic evaluation, the distinction between related and unrelated diseases becomes
irrelevant, which opens up alternative ways to estimate health care costs. Moreover, since a large part of
lifetime health care expenditure depends on time to death (Zweifel et al., 1999; Polder et al., 2006) this
implies that probably more costs are then labelled ‘related’ than currently assumed in most cost
effectiveness analyses, which usually only include the costs of diseases that are treated with the
intervention. Modelling costs exclusively conditional on age and time to death seems to have most value
for economic evaluations that track costs and effects over the follow-up period and use modelling to
extrapolate lifelong health gains. In those circumstances, no effort is made to distinguish between the
effects of the intervention on the costs of different diseases. If survival is modelled for both the control
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and the treatment group beyond follow-up, these survival curves simply can be coupled to age-speciﬁc
costs of decedents and survivors. While this approach is simple to develop and can be applied similarly
across a range of interventions, it does have an important limitation. In the proximity to death approach,
the relationship between age, mortality and health care costs is assumed ﬁxed and does not discriminate
between interventions that differ in their effect on related diseases. Using a disease-speciﬁc model does
allow expensive causes of death to be replaced by cheaper causes of death and vice versa. If these types of
mechanisms are expected to be inﬂuential, a disease-speciﬁc approach is preferred and disease-speciﬁc
estimates of the relationship between age, mortality and health care costs would be required.
Note that this paper has focused solely on indirect health care costs and ignored indirect non-medical
costs, in line with most of the ‘red herring’ literature. While it is important to further the debates and
practice in the area of indirect medical costs, we wish to stress that non-medical costs might, for some
applications, be an even more important cost category. In that area, there is still much theoretical
discussion (Meltzer, 1997; Nyman, 2004; Lee, 2008; Feenstra et al., 2008) regarding whether these costs
should indeed be included in an economic evaluation, which obviously also relates to the perspective
chosen for the evaluation. As yet, only few empirical studies (Meltzer, 1997 being a notable exception)
have attempted to address this topic more systematically, but we would encourage a broadening of the
scope of current debates to include these costs as well.
Concluding, it is clear that if unrelated costs in life years gained are to be included in economic
evaluations, the question of how they should be included is not straightforwardly answered. Researchers
obviously should be aware of postponement mechanisms in the costs of related and unrelated diseases
and as such should carefully choose and justify their method of inclusion of costs in life years gained to
avoid double counting or overstatement of ICERs. With the growing consensus on the inclusion of
unrelated costs in life years gained, it is likely that their inclusion will be facilitated through new
research and standardisation of methodology in the coming years. In the end, this will result in better
estimates of cost-effectiveness of interventions, and as such, may contribute to the ultimate aim, i.e. an
optimal allocation of scarce resources in the health care sector.
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APPENDIX A
To estimate QALYs and health care costs for the current practice and intervention scenario, the RIVM
Chronic Disease Model (CDM) was used (Hoogenveen et al., in press; van Baal et al., 2006;
Hoogenveen et al., 2008). The CDM is a tool to describe the morbidity and mortality effects of risk
factors for chronic diseases, including smoking and overweight and has been used for projections of risk
factor and disease prevalence and cost effectiveness analysis (van Baal et al., 2006, 2007a; Feenstra
et al., 2001, 2005; Struijs et al., 2005; Jacobs-van der Bruggen et al., 2007). The model describes the life
course of cohorts in terms of changes between risk factor classes and changes between disease states
over time. The model allows for co-morbidity and includes data on the most important chronic diseases
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and their risk factors. Risk factors and diseases are linked through relative risks on disease incidence
with the relative risks of former smokers on 14 smoking-related disease declining from the risk of a
smoker to that of a never smoker as a function of time since cessation. Restart rates of former smokers
are also a function of the time since smoking cessation. Since the presence of a disease increases
mortality rates, risk factor levels inﬂuence mortality through disease incidence.
A.1. Calculating health care costs with the RIVM chronic disease model (CDM)
To estimate health care costs for different scenarios with the CDM data of the Costs of Illness (COI) in
the Netherlands study were used (Slobbe et al., 2006). In that study the total direct health care costs in
the Netherlands of 2003 are uniquely attributed to disease categories speciﬁed by gender and age classes.
For the current study the COI data were partitioned in different ways to estimate lifetime health care
costs in different manners.
A.1.1. Partitioning costs to age. As a ﬁrst step, age and sex-speciﬁc average health care costs per person
are calculated using COI data in the following manner (note: all input parameters and model calculations





where ac is the average health care costs per person, COI(d) is the health care costs for disease d in 2003
and pop is the population size in the Netherlands in 2003.
Age and sex-speciﬁc health care costs deﬁned as sum of health care costs over all diseases are divided by
population numbers to obtain average health care costs per person. Average health care costs per person




ð11drÞðt1Þ  sðtjxÞ  ac
where s(t|x) is the number of survivors year t estimated with the CDM under intervention x, m is the
time horizon and dr is the discount rate.
A.1.2. Partitioning costs to age stratiﬁed to survivors and decedents. To estimate age and sex-speciﬁc
health care costs for survivors, COI data are partitioned in the following manner:
sc ¼
ac
11ðz 1Þ  k
dc ¼sc  z
where sc is the average health care costs survivors, z is the ratio of costs per year (decedents/survivors),
k is the mortality rate in 2003, and dc is the average health care costs decedents.
Costs for survivors and decedents are calculated using mortality rates for 2003 in the Netherlands
(Statistics Netherlands, 2006) and the ratio between health care costs for those dying at a particular age
and those surviving at that age. This ratio has been estimated for the Netherlands (Polder et al., 2006).
Age and sex-speciﬁc average costs for survivors then serve as input for the model to calculate lifetime








ð11drÞðt1Þ  ½sðtjxÞ  sðt 1jxÞ  dc
POSTPONEMENT OF HEALTH CARE COSTS 443
Copyright r 2010 John Wiley & Sons, Ltd. Health Econ. 20: 432–445 (2011)
DOI: 10.1002/hec
A.1.3. Partitioning costs to related and unrelated diseases. To assign the COI data that give total costs





where rc(e) is the costs per year per patient for related disease e, COI(e) total costs related disease e in
2003, p(e) is the prevalence number of related disease e in 2003.
Given the estimated costs per patient per disease per year we can write the lifetime health care costs







pðe; tjxÞ  rcðeÞ
where p(e,t) is the prevalence number of related disease e in year t estimated with the CDM.
We did not have data to estimate the relationship between proximity to death and the costs of
unrelated diseases. The model we used for the example explicitly modelled 14 smoking-related diseases
(e.g. coronary heart disease, stroke, COPD and lung cancer) that account for more than two thirds of
mortality in the Netherlands. In accordance with our theoretical framework, we hypothesised that the
relation between health care costs and proximity to death would be absent if the costs of related diseases
are excluded. Hence, we assumed that the costs of unrelated diseases were not related to proximity to
death and only depend on age. To calculate health care costs for all unrelated diseases, the numbers of
survivors were multiplied by age and sex-speciﬁc average health care costs for other diseases (i.e. costs





where uc is the annual health care costs per person for all unrelated diseases.
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